PPARG and diabetes mellitus: PPARγ agonists can promote adipose tissue to absorb and store FFAs and meanwhile inhibit liver fatty acid synthesis [25] via activating the AMP activated protein kinase (AMPK), of which the synthetic PPARγ ligand (TZDS) has been used in the treatment of diabetes for many years.